Andy Serkis to Receive IBC’s Highest Award
The IBC2019 International Honour for Excellence will go to Andy Serkis, the director, producer and actor who is today best known for his performance capture roles. These include Gollum, Supreme Leader Snoke, King Kong and Caesar in the Planet of the Apes series. Serkis will accept the award at the climax of the IBC2019 Awards Ceremony, on Sunday night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005738/en/
Andy Serkis (Photo: Business Wire)
“IBC is where the technology, the craft and the business of the media industry come together,” said Michael Crimp, CEO of IBC. “The International Honour for Excellence has a long history of rewarding those who have transformed our creative vision. Andy Serkis has achieved this by bringing extraordinary humanity to computer-generated characters.”
Serkis was born in England in 1964 and wanted to be an artist before becoming an actor, working in the theatre and on television. Today he is also a producer and director, with his London-based company Imaginarium Studios producing last year’s Mowgli, Legend of the Jungle, a new interpretation of Kipling’s originals adapted by Serkis, which also featured him co-starring as Baloo the bear alongside Christian Bale’s Bagheera.
His greatest achievement, though, is in making the shift from mere motion capture for CGI towards a combination of technology and the interpretive skill of the actor to create the fidelity of the performance in every detail. This is what gives the performance genuine humanity: his performance as Caesar in the three Planet of the Apes films won him an acting nomination from the Broadcast Film Critics Association.
For bringing together the highest performance standards with the latest in image recognition and CGI technology, the IBC2019 International Honour for Excellence will be presented to Andy Serkis.
“I feel incredibly honoured to have been chosen as the recipient of this year’s prestigious IBC award,” said Andy Serkis. “In turn, I must share this appreciation with the phenomenal legions of creative artists, visionaries and pioneers with whom I’ve been lucky enough to dance with on this journey of next generation storytelling.”
The IBC2019 Awards Ceremony is free to all IBC visitors. It takes place on Sunday evening 15 September at 18.30 in the RAI Auditorium, and will also see the presentation of two new awards this year, honouring achievements in social responsibility and a Young Pioneer, alongside the IBC Innovation Awards.
Earlier on Sunday Andy Serkis will feature in an IBC2019 Conference Convention Keynote , in conversation with Hollywood journalist Carolyn Giardina. They will review his career, the state of the art in motion capture, and discuss where he sees the future of technology in film and television. The Convention Keynote is at 12.30 in the Forum, and is free to attend.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005738/en/
Contact information
Aimee Moore
amoore@ibc.org
+44 (0) 20 7832 4104
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 20:20:00 EET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom